Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H553

UPID:
ALG2_HUMAN

ALTERNATIVE NAMES:
Asparagine-linked glycosylation protein 2 homolog; GDP-Man:Man(1)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase; GDP-Man:Man(1)GlcNAc(2)-PP-dolichol mannosyltransferase; GDP-Man:Man(2)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase

ALTERNATIVE UPACC:
Q9H553; A2A2Y0; Q8NBX2; Q8NC39

BACKGROUND:
The enzyme Alpha-1,3/1,6-mannosyltransferase ALG2 plays a crucial role in the synthesis of glycoproteins, essential for proper cellular function and development. By facilitating the addition of mannose to dolichol-linked oligosaccharides, ALG2 is integral to N-glycosylation, a process vital for protein folding and stability.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Alpha-1,3/1,6-mannosyltransferase ALG2 could open doors to potential therapeutic strategies. Its direct association with diseases like Congenital disorder of glycosylation 1I and congenital myasthenic syndrome, congenital, 14, positions ALG2 as a target for developing treatments aimed at mitigating these severe conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.